Multicenter phase II trial of combination therapy with meloxicam, a COX-2 inhibitor, and natural interferon-α for metastatic renal cell carcinoma

Japanese Journal of Clinical Oncology

Volumn 39, Issue 11, 2009, Pages 720-726

  Shinohara, Nobuo ^a   Kumagai, Akira ^b   Kanagawa, Kouichi ^c   Maruyama, Satoru ^a   Abe, Takashige ^a   Sazawa, Ataru ^a   Nonomura, Katsuya ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b TEINE KEIJINKAI HOSPITAL   (Japan)

^c Asahikawa City Hospital   (Japan)

Author keywords

Clinical trial; COX 2 inhibitor; CRP; IFN ; Renal cell carcinoma

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; MELOXICAM;

ADRENAL METASTASIS; ADULT; AGED; ANOREXIA; ARTHRITIS; ARTICLE; BONE METASTASIS; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DEPRESSION; DERMATITIS; DISEASE DURATION; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FLU LIKE SYNDROME; HUMAN; KIDNEY CARCINOMA; LIVER DYSFUNCTION; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; MULTICENTER STUDY; NEPHRECTOMY; PANCREAS DISEASE; PEPTIC ULCER; PHASE 2 CLINICAL TRIAL; PROTEIN BLOOD LEVEL; SIDE EFFECT; SKIN METASTASIS; SOFT TISSUE METASTASIS; STOMACH ULCER; VERTIGO;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; CYCLOOXYGENASE 2 INHIBITORS; DISEASE-FREE SURVIVAL; FATIGUE; FEMALE; HUMANS; INTERFERON-ALPHA; KAPLAN-MEIERS ESTIMATE; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; THIAZINES; THIAZOLES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 70449333312     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyp089     Document Type: Article

References (25)

1. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002;20:289-96.
2. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115-24.
3. Figlin A, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Negrier S, et al. Overall survival with sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC). J Clin Oncol 2008;26:256s (suppl; abstr 5024).
4. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, et al. Global ARCC Trial. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356:2271-81.
5. Gollob JA, Rathmell WK, Richmond TM, Marino CB, Miller EK, Grigson G, et al. Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer. J Clin Oncol 2007;25:3288-95.
6. Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, et al. AVOREN Trial Investigators. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: A randomised, double-blind phase III trial. Lancet 2007;370:2103-11.
7. Chen Q, Shinohara N, Abe T, Watanabe T, Nonomura K, Koyanagi T. Significance of COX-2 expression in human renal cell carcinoma cell lines. Int J Cancer 2004;108:825-32.
8. Chen Q, Shinohara N, Abe T, Harabayashi T, Nonomura K. Impact of cyclooxygenase-2 gene expression on tumor invasiveness in a human renal cell carcinoma cell line. J Urol 2004;172:2153-7.
9. Tuna B, Yorukoglu K, Gurel D, Mungan U, Kirkali Z. Significance of COX-2 expression in human renal cell carcinoma. Urology 2004;64:1116-20.
10. Rini BI, Weinberg V, Dunlap S, Elchninoff A, Yu N, Bok R, et al. Maximal COX-2 immunostaining and clinical response to celecoxib and interferon alpha therapy in metastatic renal cell carcinoma. Cancer 2006;106:566-75.
11. Yoshino S, Okabe T. Advanced renal cell carcinoma in which a combination of IFN-alpha and meloxicam was thought to be effective. Int J Urol 2003;10:52-5.
12. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92: 205-16.
13. Kinouchi T, Sakamoto J, Tsukamoto T, Akaza H, Kubota Y, Ozono S, et al. Immunotherapy Oncology Group for Renal Cell Carcinoma. Prospective randomized trial of natural interferon-alpha versus natural interferon-alpha plus cimetidine in advanced renal cell carcinoma with pulmonary metastasis. J Cancer Res Clin Oncol 2006;132:499-504.
14. Sagaster P, Micksche M, Flamm J, Ludwig H. Randomised study using IFN-alpha versus IFN-alpha plus coumarin and cimetidine for treatment of advanced renal cell cancer. Ann Oncol 1995;6:999-1003.
15. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989;10:1-10.
16. Naito S, Yamamoto N, Takayama T, Muramoto M, Shinohara N, Nishiyama K, et al. Prognosis of Japanese metastatic renal cell carcinoma patients in the cytokine era: A cooperative group report of 1463 patients. Eur Urol 2009; doi:10.1016/j.eururo.2008.12.026.
17. Atkins M, Regan M, McDermott D, Mier J, Stanbridge E, Youmans A, et al. Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin Cancer Res 2005;11:3714-21.
18. Negrier S, Escudier B, Lasset C, Douillard JY, Savary J, Chevreau C, et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie. N Engl J Med 1998;338:1272-8.
19. Akaza H, Tsukamoto T, Onishi T, Miki T, Kinouchi T, Naito S. A low-dose combination therapy of interleukin-2 and interferon-α is effective for lung metastasis of renal cell carcinoma: A multicenter open study. Int J Clin Oncol 2006;11:434-40.
20. Miyake H, Kurahashi T, Takenaka A, Inoue T, Fujisawa M. Clinical outcome of combined immunotherapy with interferon-a and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma. Urol Oncol 2008; Sep 23 (Epub ahead of print).
21. DeLong P, Tanaka T, Kruklitis R, Henry AC, Kapoor V, Kaiser LR, et al. Use of cyclooxygenase-2 inhibition to enhance the efficacy of immunotherapy. Cancer Res 2003;63:7845-52.
22. Atzpodien J, Royston P, Wandert T, Reitz M. DGCIN - German Cooperative Renal Carcinoma Chemo-Immunotherapy Trials Group. Metastatic renal carcinoma comprehensive prognostic system. Br J Cancer 2003;88:348-53.
23. Yoshida N, Ikemoto S, Narita K, Sugimura K, Wada S, Yasumoto R, et al. Interleukin-6, tumour necrosis factor alpha and interleukin-1beta in patients with renal cell carcinoma. Br J Cancer 2002;86:1396-400.
24. Ramsey S, Aitchison M, Graham J, McMillan DC. The longitudinal relationship between the systemic inflammatory response, circulating T-lymphocytes, interleukin-6 and -10 in patients undergoing immunotherapy for metastatic renal cancer. BJU Int 2008;102:125-9.
25. Smyth GP, Stapleton PP, Barden CB, Mestre JR, Freeman TA, Duff MD, et al. Renal cell carcinoma induces prostaglandin E2 and T-helper type 2 cytokine production in peripheral blood mononuclear cells. Ann Surg Oncol 2003;10:455-62.